The logo of Lupin as seen on the facade of its pharmaceutical plant in Verna, in Goa, India. Image for representational purpose
| Photo Credit: Reuters
Generic drugmaker Lupin has launched Rivaroxaban for Oral Suspension, 1 mg/mL, in the U.S.
The product is bioequivalent to Xarelto for Oral Suspension, 1 mg/mL of Janssen Pharmaceuticals, Inc. Rivaroxaban for Oral Suspension, 1 mg/mL (reference listed drug Xarelto) had estimated annual sales of $11 million in the U.S., Lupin said, citing IQVIA MAT July 2025 numbers.
Rivaroxaban for Oral Suspension is indicated for treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in paediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment; and treatment of thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure, it said.
Published – October 01, 2025 08:28 pm IST
